JonesResearch analyst Justin Walsh initiated coverage of Y-mAbs Therapeutics with a Buy rating and $23 price target. Y-mAbs is a commercial stage biopharmaceutical company developing and commercializing radioimmunotherapy and antibody-based therapeutic agents for the treatment of cancer, the analyst tells investors in a research note. The firm anticipates a steady pace of clinical updates to drive value in the shares, noting multiple SADA PRIT assets are advancing into and through the clinic and Danyelza is being tested in additional indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift
- Y-mAbs Therapeutics appoints Peter Pfreundschuh as CFO
- Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
- Y-mAbs Therapeutics initiated with a Buy at Truist
- Y-mAbs Therapeutics announces preclinical GD2-SADA to be presented at SNMMI